Cardiac safety concerns stand at the forefront of the factors causing setbacks or even discontinuation of promising drugs during their development, preventing them from reaching the market. One of the contributing factors to this issue is the unreliability of site devices, which can result in inadequate inclusion and exclusion criteria as well as enrollment decisions. Consequently, these challenges pose potential risks to patients participating in the studies and could generate misleading data.
Navigating through this intricate regulatory landscape while addressing safety issues requires specialized expertise to effectively mitigate risks and accelerate the process of bringing clinical treatments to market. By seeking expert guidance, teams can ensure a faster and more confident journey toward making these treatments available to those in need.
Access the brochure below to get an overview of how Clario’s in-house, world-renowned cardiac safety consultants can do to ensure quality outcomes in your next clinical trial.